Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 69   

Articles published

PFE 30.35 -0.10 (-0.31%)
price chart
Verastem Acquires Clinical-Stage FAK Inhibitor from Pfizer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc., (NASDAQ: VSTM) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced an agreement with Pfizer for ...
Verastem Enters Agreement With Pfizer For Worldwide Commercial Right For VS ...  RTT News
Verastem Inks Separate Deals for Wnt and FAK Inhibitors  Genetic Engineering News
Related articles »  
Pfizer Announces Topline Results Of First Of Four Studies In Bapineuzumab ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the co-primary clinical endpoints, change in cognitive and functional performance compared to placebo, were not met in the Janssen Alzheimer Immunotherapy R&D LLC ...
Pfizer-J&J Alzheimer's Drug Fails to Aid Cognition  Bloomberg
Pfizer, J&J Alzheimer's drug fails one of four big trials  Reuters
Related articles »  
Is Pfizer A Good Buy?
Pfizer has been involved in a series of acquisitions and sell offs, some cheered and some criticized by investors. They recently sold off their nutrition business to Nestle for $11.9 billion.
Pfizer Defends $25 Fair Value With Lyrica Patent Lawsuit Win  Trefis
Pfizer Needs Big Earnings Beat  TheStreet.com
Related articles »  
For Pfizer, Boston's medical labs a lure
Pfizer Inc., the world's largest pharmaceutical company, has a storied history of hunting for blockbuster drugs in its own labs.
Related articles »  
Pfizer May Sink On New Drug Woes
Pfizer (PFE) has recently been struggling to get an edge in the pharmaceutical industry. Not only is it struggling to get a major drug approved, but it also is on the defensive in several ways.
Related articles »  
Why We Think Pfizer Remains Significantly Undervalued
If a company is undervalued both on a DCF and on a relative valuation basis and is showing improvement in technical and momentum indicators, it scores high on our scale.
Related articles »  
PFIZER INC. : Summary Notice Of Pendency Of Class Action
If you have not yet received the full printed Notice, you may obtain copies of this document by contacting the Notice Administrator at: Pfizer Securities Litigation, Notice Administrator, P.O. Box 3410, Portland, OR 97208-3410, (888) 236-0464, www.
Related articles »  
Pfizer to return rights to three Acura products
(Reuters) - Pfizer Inc will return three products it was developing using Acura Pharmaceuticals Inc's abuse-resistant technology, Acura said on Friday.
Related articles »  
Alnylam Pushes Forward In Amyloidosis After Pfizer Setback
Considering lack of progress in the RNAi space to date and the fact that the drug, ALN-TTR02, is one the company's biggest pipeline hopes, this makes encouraging news, particularly as a phase II study has already started.
Alnylam Gains on Treatment Data for Deadly Nerve Disease  Bloomberg
Related articles »  
Pfizer Led Corporate America's Biggest Givers Last Year
Pfizer Inc. (PFE:US), the world's largest drugmaker, was corporate America's largest donor for a third straight year, granting $3.1 billion in gifts in 2011.
Related articles »